



New Insights of Malignant Pleural Mesothelioma

Guest Editors:

Prof. Dr. Gregor J. Kocher

Department for BioMedical
Research (DBMR), Inselspital,
Bern University Hospital,
University of Bern, Murtenstrasse
28, CH3008 Bern, Switzerland

Dr. Georgia Karpathiou

Pathology, North Hospital,
University Hospital of Saint-
Etienne, 42055 Saint-Etienne,
France

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editors

Malignant pleural mesothelioma (MPM), although a relatively rare disease, is one of the most aggressive and most difficult to treat cancers affecting the thoracic cavity. While the surgical strategy, which focuses on maximal cytoreduction, has evolved from very invasive procedures such as extrapleural pneumonectomy with resection of the pericardium and diaphragm, to less invasive procedures such as pleurectomy/decortication (in selected cases even in the form of minimally invasive video-assisted procedures (VATS)), newer and less toxic systemic agents have also been developed, which are the result of a better understanding of the specific tumor biology. The molecular and morphologic features of this disease are being progressively elucidated and offer a more precise diagnosis.

The aim of this Special Issue is to present the newest developments concerning treatment options for MPM, including basic and translational research, and clinical data of different surgical and combination strategies, but also insights into its pathogenesis, molecular biology, pathology, and diagnosis. In this Special Issue, original research articles and reviews are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)